Data on the Anti-inflammatory Activity of Cempra Pharmaceutical's CEM-101 Will be Presented at the American Thoracic Society 2010 International Conference
CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals
today announced the schedule of poster presentations on its
next-generation macrolide, CEM-101, at the American Thoracic
Society (ATS) 2010 International Conference in New Orleans,
Louisiana, on May 14 to 19, 2010.
Both posters will be presented during the poster session
entitled "C41 Emerging Pharmacology for Chronic Obstructive
Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m.
to 4:00 p.m. CDT on Tuesday, May 18.
Cempra Pharmaceuticals ATS 2010 International Conference
Schedule At-A-Glance
Tuesday, May 18, 2010 -- Poster Presentation: "A novel macrolide/ fluoroketolide, CEM-101, reverses corticosteroid insensitivity under oxidative stress, via PI3K pathway inhibition" Time: On display: 8:15 a.m. to 4:00 p.m. CDT, Poster # 3527 Location: F62, Area F, Hall G Y. Kobayashi, C. Rossios, D. Takagi, P.J. Barnes, K. Ito (Airway Disease Section, NHLI, Imperial College London, UK) -- Poster Presentation: "Superior anti-inflammatory effects of a novel macrolide/fluoroketolide, CEM-101 in monocytic cells" Time: On display: 8:15 a.m. to 4:00 p.m. CDT, Poster # 3506 Location: F63, Area F, Hall G Y. Kobayashi, C. Rossios, P.J. Barnes, K. Ito (Airway Disease Section, NHLI, Imperial College London, UK) About CEM-101
CEM-101 is a next generation macrolide with a number of
attributes that may provide clinically important advantages over
several comparator products:
-- Potent activity, in vitro and in vivo, against all important pathogens
that cause community-acquired bacterial pneumonia, including
pneumococci, as well as potent activity against a broad spectrum of
other serious pathogens including CA-MRSA, M. avium, malaria, atypical
bacteria such as Legionella, Mycoplasma, Chlamydophila, and Neisseria
-- CEM-101 is generally 8 to 16 times more potent than azithromycin and
is active against organisms that have become resistant to azithromycin
-- Novel structure and mechanism of action with additional binding sites
on the bacterial ribosome that confers activity against erm- and
mef-resistant strains
-- Good tolerability in phase 1 trials
-- Low resistance frequency in vitro
-- Excellent tissue distribution and intracellular tissue concentrations
-- Oral and IV formulations
-- Once-daily dosing
-- Potential for indications beyond CABP, including urethritis and other
urogenital infections, bioterrorism targets, malaria, M. avium
infections and tuberculosis
The annual incidence for pneumonia in the United States is over
5 million patients each year. There is a growing need for new drugs
to address the issues of drug resistance, tolerability, and
administration associated with currently available treatments.
Cempra has licensed exclusive worldwide rights from Optimer
Pharmaceuticals, Inc., except in the Association of Southeast Asian
Nations (ASEAN) countries, to discover, develop and commercialize
macrolides from a library of more than 500 compounds from Optimer's
OPopS drug discovery platform.
About Cempra Pharmaceuticals
Founded in 2006, Cempra Pharmaceuticals is a privately-held,
clinical-stage pharmaceutical company focused on developing
antibacterials to address critical medical needs. Two lead
products, both in late-stage clinical trials, address the urgent
and increasing need for new treatments targeting drug-resistant
bacterial infections in the hospital and in the community. Cempra
is well-funded and is committed to developing commercially and
medically differentiated and novel products that reduce development
risk and provide a high financial return. The company is also
utilizing its proprietary compound library and chemistry technology
to develop novel macrolides without antibacterial activity for
non-antibiotic uses such as COPD, chronic inflammatory and GI
disorders. Additional information about Cempra can be found at
www.cempra.com.
Media Contacts: Robert E. Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 Robert.flamm@russopartnersllc.com Tony Russo, Ph.D. Russo Partners, LLC (212) 845-4251 Tony.russo@russopartnersllc.com
Source: Cempra Pharmaceuticals
CONTACT: Robert E. Flamm, Ph.D., Russo Partners, LLC,
+1-212-845-4226,
Robert.flamm@russopartnersllc.com;
Tony Russo, Ph.D., Russo Partners, LLC,
+1-212-845-4251, Tony.russo@russopartnersllc.com
Web Site: http://www.cempra.com/
Posted: May 2010
